Nothing Special   »   [go: up one dir, main page]

MX2021009528A - Prueba de diagnostico basada en fragmento de rgma. - Google Patents

Prueba de diagnostico basada en fragmento de rgma.

Info

Publication number
MX2021009528A
MX2021009528A MX2021009528A MX2021009528A MX2021009528A MX 2021009528 A MX2021009528 A MX 2021009528A MX 2021009528 A MX2021009528 A MX 2021009528A MX 2021009528 A MX2021009528 A MX 2021009528A MX 2021009528 A MX2021009528 A MX 2021009528A
Authority
MX
Mexico
Prior art keywords
diagnostic assay
based diagnostic
fragment based
rgma fragment
rgma
Prior art date
Application number
MX2021009528A
Other languages
English (en)
Inventor
Stefan Barghorn
Andreas Striebinger
Martin Schmidt
Bernhard Klaus Mueller
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MX2021009528A publication Critical patent/MX2021009528A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

Se proveen pruebas de diagnóstico y métodos para utilizar las pruebas de diagnóstico para detectar y cuantificar fragmentos de RGMa en una muestra. Los métodos se pueden utilizar en la detección de los fragmentos de RGMa para monitorear el tratamiento con fármaco y la efectividad del tratamiento con fármaco en enfermedades neurodegenerativas.
MX2021009528A 2014-09-10 2017-03-08 Prueba de diagnostico basada en fragmento de rgma. MX2021009528A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462048745P 2014-09-10 2014-09-10

Publications (1)

Publication Number Publication Date
MX2021009528A true MX2021009528A (es) 2021-09-08

Family

ID=54064367

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003063A MX2017003063A (es) 2014-09-10 2015-09-09 Prueba de diagnostico basada en fragmento de rgma.
MX2021009528A MX2021009528A (es) 2014-09-10 2017-03-08 Prueba de diagnostico basada en fragmento de rgma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017003063A MX2017003063A (es) 2014-09-10 2015-09-09 Prueba de diagnostico basada en fragmento de rgma.

Country Status (10)

Country Link
US (3) US20160069907A1 (es)
EP (1) EP3191847A1 (es)
JP (1) JP6879905B2 (es)
CN (2) CN107076757A (es)
AU (2) AU2015314240A1 (es)
BR (1) BR112017004883A2 (es)
CA (1) CA2956814A1 (es)
MX (2) MX2017003063A (es)
TW (2) TW201617612A (es)
WO (1) WO2016038084A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
MX2012006560A (es) * 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
CN112566664B (zh) 2018-07-19 2023-08-25 国立大学法人东京大学 Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法
WO2021145432A1 (ja) * 2020-01-15 2021-07-22 国立大学法人大阪大学 糖尿病性自律神経障害の予防又は治療剤
CN112402554B (zh) * 2020-10-26 2022-03-01 中国中医科学院广安门医院 一种治疗脑白质病的中药组合物及其应用
WO2023004436A1 (en) * 2021-07-23 2023-01-26 Cedars-Sinai Medical Center Methods and systems for early detection of ocular and/or neurological conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754062B2 (en) * 1998-07-03 2002-10-31 Innogenetics N.V. Differential diagnosis of neurodegeneration
WO2002051438A2 (en) * 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
KR20120120193A (ko) * 2009-12-09 2012-11-01 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
AU2011285852B2 (en) * 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012047706A2 (en) * 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
EP2723866B1 (en) * 2011-06-22 2018-03-28 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
SG10201600316SA (en) 2012-01-27 2016-02-26 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration

Also Published As

Publication number Publication date
CN107076757A (zh) 2017-08-18
JP6879905B2 (ja) 2021-06-02
AU2015314240A1 (en) 2017-02-09
MX2017003063A (es) 2017-06-14
EP3191847A1 (en) 2017-07-19
CA2956814A1 (en) 2016-03-17
WO2016038084A1 (en) 2016-03-17
JP2017526930A (ja) 2017-09-14
AU2022200160A1 (en) 2022-02-10
CN113267630A (zh) 2021-08-17
US20200241012A1 (en) 2020-07-30
TW201617612A (zh) 2016-05-16
US20160069907A1 (en) 2016-03-10
BR112017004883A2 (pt) 2017-12-05
TW202119030A (zh) 2021-05-16
US20220018855A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
HK1257999A1 (zh) 用於臨床應用的分析物收集、提取、濃縮和檢測的方法和裝置
HK1214671A1 (zh) 輔助疾病診療的分析系統、裝置及方法
CL2017003069A1 (es) Métodos para diagnosticar y tratar el cáncer.
GB2552267B (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
SG11201609288YA (en) Fully-automatic immunofluorescence quantitative analysis device and detection method
SG10201408391RA (en) Means and methods for multimodality analysis and processing ofdrilling mud
EP3482209C0 (en) ALPHA SYNUKLEIN DETECTION TEST AND METHOD FOR DIAGNOSING ALPHA SYNUKLEINOPATHIES
EP3186397C0 (en) USE OF BIOMARKERS OF CIRCULATING CELLS IN THE BLOOD FOR THE DETECTION AND DIAGNOSIS OF DISEASES, AND THEIR ISOLATION PROCESSES
PH12017501967A1 (en) Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof
EP3209998A4 (en) Method and system for detection of disease agents in blood
IL265712B (en) A method for identifying active forms of an analyte and determining the ability of substances to bind with active sites of an analyte
EP3200118A4 (en) Sample traceability device and method for medical research and/or diagnosis
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
HK1214649A1 (zh) 體外診斷分析方法和系統
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
BR112016028838A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
WO2015042326A3 (en) Methods for detection and treatment of neurodegenerative diseases
SG11201509866TA (en) Protease-responsive peptide biosensors and methods for analyte detection
IN2014KN00742A (es)
EP3206032A4 (en) Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure
GB2530521B (en) Mass spectral analysis of patient samples for the detection of the human chorionic gonadotropin
SG11201700424XA (en) Detection method using recombinant living cells for detecting xenobiotic substances and arrangement and test kit for performing the detection method
EP3093662A4 (en) 5-hydroxy-1h-imidazole-4-carboxamide effective-dose/sensitivity prediction method and prediction device, xanthosine-monophosphate-amount measurement method, and myelodysplastic-syndrome treatment agent and treatment method